I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
4.870
-0.290 (-5.62%)
Aug 15, 2025, 3:46 PM - Market open
I-Mab Employees
I-Mab had 32 employees as of December 31, 2024. The number of employees decreased by 188 or -85.45% compared to the previous year.
Employees
32
Change (1Y)
-188
Growth (1Y)
-85.45%
Revenue / Employee
n/a
Profits / Employee
-$283,219
Market Cap
560.02M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 32 | -188 | -85.45% |
Dec 31, 2023 | 220 | -158 | -41.80% |
Dec 31, 2021 | 378 | 150 | 65.79% |
Dec 31, 2020 | 228 | 43 | 23.24% |
Dec 31, 2019 | 185 | 51 | 38.06% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IMAB News
- 14 days ago - Everest Medicines Expands Strategic Investment in I-MAB - PRNewsWire
- 14 days ago - I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares - GlobeNewsWire
- 4 weeks ago - I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health - GlobeNewsWire
- 6 weeks ago - I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 - GlobeNewsWire
- 6 weeks ago - I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research - GlobeNewsWire
- 7 weeks ago - I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 - GlobeNewsWire
- 3 months ago - I-Mab to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire